Among the programs involved are therapies for multiple myeloma and B-cell malignancies.
Pre-clinical data showed that EZ-T cells have increased anti-tumor activity compared with traditional iPSC-derived T-cells.
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.